Featured Post from ChristianaCare

Peer Support Program Helps Patients With Substance Use Disorders

Nov 17, 2023

4 min

Recognizing that stigma may keep people from accessing treatment and recovery resources, ChristianaCare Union Hospital is partnering with the Cecil County Health Department and Voices of Hope to make peer recovery specialists available at the bedside for patients who have experienced a drug overdose or live with substance use disorder.


Ten peer recovery specialists are available at Union Hospital seven days a week from 8:30 a.m. to 1 a.m. to talk with patients about behavioral health care navigation, access to treatment and referrals to harm-reduction and recovery-support resources. Patients can be connected with a certified peer recovery specialist if they are brought to the Emergency Department because of a drug overdose, or if they screen positive for substance use while they are a patient in the hospital.


ChristianaCare Union Hospital is partnering with the Cecil County Health Department and the Maryland nonprofit Voices of Hope to make peer recovery specialists, pictured in blue t-shirts, available at the bedside for patients who have experienced a drug overdose or live with substance use disorder.



Patients are not required to speak with a peer recovery specialist, but the specialists’ unique combination of lived experience and training to help people experiencing behavioral health issues offers an opportunity for people with substance use disorder to get help without fear of judgment or stigma.


“Substance use disorder continues to be a serious health problem that affects people of all ages and walks of life,” said Lanre Akinkunmi, M.D., interim chief medical officer and medical director for population health at ChristianaCare Cecil County Campus. “The good news is that it is treatable, and when people are in the hospital or the emergency department, they are often most receptive to discussions about treatment. Through this expanded use of peer recovery specialists at Union Hospital, we are making a positive impact on the health of our patients and our community.”


A voice of experience


Peer recovery specialists who work on the weekdays are employed by the Cecil County Health Department, supported by a grant from the National Association of County and City Health Officials. Voices of Hope, a nonprofit focused on recovery support for people in Harford and Cecil counties in Maryland, employs the peer specialists working evenings and weekends.


“This program is a great example of using resources wisely and effectively. We already know the tremendous work being done by Voices of Hope and Cecil County Health Department to help our neighbors who have been impacted by substance use disorder,” said Lisa Fields, manager of Community Engagement at the Cecil County Campus. “By partnering on this important program, we are building trust with our patients and helping them to get on the road to recovery.”


Since the expanded program launched in September, there have been about 40 referrals for patients to speak with peer support specialists, and more than half of them have agreed to some kind of treatment, Fields said.


Unique connection


“Helping people get through what I went through really warms my heart,” said Hannah Dean, a peer recovery specialist with the Cecil County Health Department who works at Union Hospital. “I love what I do.”


Cecil County’s death rate from drug overdoses is nearly twice as high as the rest of Maryland and more than three times the U.S. rate. The drug overdose death rate in Cecil County more than doubled between 2016 and 2020, according to the 2022 Cecil County Community Health Needs Assessment.


Because peer support specialists have lived experience with substance use disorder and recovery, along with specialized training to support people struggling with mental health or substance use issues, they can connect with patients on a personal level and offer empathetic guidance, said Lauren Levy, health officer for the Cecil County Health Department.


“Allowing peer recovery specialists to engage bedside with patients who may be struggling with substance use disorders will not only enhance access to behavioral health treatment but will also help reduce stigma surrounding substance use disorders and foster a more compassionate and supportive community,” Levy said.


“We are honored to be a part of this innovative private-public collaboration and to work alongside ChristianaCare Union Hospital and Voices of Hope, Inc. This project helps to break down barriers to treatment and provide immediate support to those in need.”


A history of support


ChristianaCare has long been a pioneer in the use of peer recovery specialists, going back to the launch of Project Engage at ChristianaCare’s Wilmington Hospital in 2008.


Union Hospital first partnered with the Cecil County Health Department 10 years ago to provide a peer recovery specialist in the Emergency Department. That program, the first of its kind in Maryland, was recognized with a best practice award from the Maryland Association of Counties in 2014. However, it operated only on weekdays during daytime business hours, and its ability to connect with hospital patients slowed during the COVID-19 pandemic.


This reinvigorated peer recovery program is strengthened by the high level of collaboration among these Cecil County organizations, said Erin Wright, chief operations officer for Voices of Hope.


“As community-based organizations, we are in a position to make a difference, and our perspective in the care for people with substance use disorder is really valuable,” said Wright, who has been in recovery for eight years.


“As someone who has been through it, we are able to have that empathy. Even if the person does not want to go to treatment, you sit with them and maybe plant a seed.”


Catharine Murray hopes her role as a certified peer recovery specialist can help someone struggling with addiction see recovery as a viable option for themselves.


“This wasn’t available to me when I was trying to get better. I want to make it more accessible to others,” she said.

Powered by

You might also like...

Check out some other posts from ChristianaCare

3 min

New Study Finds Most Patients Can Safely Continue Weight Loss and Diabetes Drugs Before Gynecologic Surgery

Most patients taking popular weight loss and diabetes medications such as Ozempic and Wegovy can safely continue them before gynecologic surgery, according to a new journal article from ChristianaCare published in Obstetrics & Gynecology. The review found that serious anesthesia risks linked to these drugs are uncommon for most patients and can usually be managed through individualized planning rather than stopping the medication. The paper is the first to take a focused look at glucagon-like peptide-1 receptor agonists, commonly called GLP-1 drugs, in gynecologic surgery. These medications were first approved to treat diabetes and are now widely used to support weight loss and metabolic health, which refers to how the body processes sugar and energy. “Our study shows that the evidence does not support routinely stopping these medications before surgery and that the actual risk is low for most patients,” said Michelle Pacis, M.D., MPH, senior author of the study and a minimally invasive gynecologic surgeon at ChristianaCare. Why these medications raised concerns GLP-1 drugs work in part by slowing how quickly the stomach empties. This helps patients feel full longer, but it also raises concerns for surgery. Doctors worry that food remaining in the stomach could increase the risk of aspiration, when stomach contents enter the lungs during anesthesia. Because of this, early recommendations often advised stopping GLP-1 medications before surgery. The ChristianaCare review found that this approach was largely based on caution rather than strong evidence. The authors reviewed data from multiple studies, including large patient groups, that examined outcomes in people taking GLP-1 drugs during procedures. While some studies showed higher amounts of stomach contents, aspiration events were rare and occurred at rates similar to patients who were not taking the medications. New guidance reflects a change in thinking Recent national guidance from several medical societies now recommends a more tailored approach. Most patients can continue GLP-1 medications before surgery. For patients with higher risk factors, such as significant stomach symptoms or known delayed digestion, simple precautions can reduce risk. These precautions may include a clear liquid diet for 24 hours before surgery or closer monitoring during anesthesia. A clear liquid diet includes fluids like water, broth and clear juices. “This shift recognizes both the benefits of these medications and the importance of patient-specific decision making,” Pacis said. Why this matters for gynecologic surgery Many gynecologic surgeries require patients to be positioned in ways that can affect breathing and circulation. At the same time, many patients needing these procedures also have obesity or diabetes, which can increase surgical risk. GLP-1 medications can improve blood sugar control and support weight loss, helping patients enter surgery in better overall health and enhance recovery. Stopping these drugs without a clear reason may work against those benefits. Practical steps to support patient safety The study outlines several strategies care teams can use when patients remain on GLP-1 medications. These include thoughtful anesthesia planning, careful monitoring of heart and lung function, and, in select cases, the use of ultrasound to check stomach contents before surgery. “The goal is not to ignore risk, but to manage it wisely,” Pacis said. “For many patients, continuing these medications supports safer surgery and better recovery.” The authors note that more research is needed, particularly studies focused specifically on gynecologic surgery. Still, the findings offer clarity for patients and clinicians navigating a rapidly changing area of care. “This review helps bring evidence and balance to an issue that has caused a lot of confusion,” Pacis said. “It supports keeping patients on therapies that benefit their health whenever it is safe to do so.”

1 min

Two Research Scientists at the Cawley Center for Translational Cancer Research Earn Top Honors at UD Biology Research Day

Two rising cancer researchers from ChristianaCare’s Cawley Center for Translational Cancer Research were recognized for outstanding scientific contributions at the University of Delaware’s Annual Biology Research Day Conference on January 30, 2026. The awards highlight the strength and impact of colorectal cancer research underway at the Cawley Center. Anh Nguyen, a third year Ph.D. student, received the conference’s first place poster award for his project, “FGF19/FGFR4 Axis: A Key Driver in Tumor Growth and Treatment Resistance in Colorectal Cancer.” His research explores a signaling pathway that may lead to new strategies for targeting treatment resistant disease. Molly Lausten, a fifth year Ph.D. student, earned third place for her presentation, “Investigating the role of miR 27a 3p in the WNT signaling pathway and chemoresistance in colorectal cancer stem cells.” Her work examines a key microRNA that may influence resistance to therapy, a major challenge in treating aggressive tumors. “These awards reflect far more than individual excellence,” said Bruce M. Boman, M.D., Ph.D., MSPH, FACP, senior scientist and director of Cancer Genetics at the Cawley Center. “They show the power of rigorous, curiosity driven science to move the field forward. Molly and Anh are tackling some of the hardest questions in colorectal cancer, and their success speaks to the innovative environment we are building at ChristianaCare. I could not be more proud of their achievement and their commitment to improving outcomes for patients.”

3 min

Gene Editing Breakthrough Offers New Hope for Head and Neck Cancer Patients

Researchers at the ChristianaCare Gene Editing Institute have made an important advance in treating head and neck cancers. By using CRISPR gene editing, the team found a way to restore how well chemotherapy works in tumors that have stopped responding to treatment. Their results, now published in Molecular Therapy Oncology, could change how doctors treat these aggressive cancers and give new hope to many patients who face limited options. Head and neck cancer is the seventh most common cancer worldwide, and cases are expected to rise by 30 percent every year by 2030. Even with progress in surgery, chemotherapy and immunotherapy, many patients still reach a point where treatment no longer works. The ChristianaCare team aimed to solve this challenge at its source. Targeting the Heart of Drug Resistance The researchers focused on a gene called NRF2. This gene acts like a master switch that helps cancer cells survive stress and resist chemotherapy. Because NRF2 plays such a central role in tumor growth, the team chose to develop a genetic therapy that disables the gene itself rather than targeting a single protein, which is common in traditional drug development. Since NRF2 is a transcription factor, shutting it down in a lasting way is more likely to succeed through CRISPR gene editing. Their major advance was showing that CRISPR can successfully disrupt NRF2 in head and neck cancer cells and in esophageal cancer cells. This work builds on earlier studies in lung cancer, where blocking NRF2 made tumors more sensitive to chemotherapy and improved survival in animal models. “Our goal was to break through the wall of drug resistance that so many patients face,” said Natalia Rivera Torres, Ph.D., the study’s lead author. “By precisely editing the NRF2 gene, we can make cancer cells vulnerable again to standard treatments. This could improve outcomes and quality of life.” Precision Matters: The Power of Target Choice The study also showed that the location of the CRISPR cut within the NRF2 gene makes a big difference. The strongest results came from targeting exon 4, a part of the gene that controls a key section of the NRF2 protein. Editing this region reduced NRF2 levels by 90 percent and made cancer cells much more sensitive to chemotherapy. In comparison, editing exon 2 was less effective even though it still caused high levels of gene disruption. The team also found that a process called exon skipping, where sections of genetic code are rearranged, can affect the outcome of gene editing. This discovery highlights how important careful design and testing are when building gene editing therapies. A Platform for Broader Impact ChristianaCare researchers saw the same results in both head and neck cancer cells and esophageal cancer cells. This suggests the strategy could help treat many solid tumors that have high levels of NRF2 and are known for strong drug resistance. “This is more than just a single experiment,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and senior author of the study. “We are building a platform that can be adapted to different cancers. Our earlier work in lung cancer showed the promise of this approach, and now we see it working in other hard to treat tumors. It is an exciting step toward making gene editing a meaningful part of cancer treatment.” Looking Ahead: Toward Clinical Application With these strong results, the team is now focused on finding the safest and most effective way to deliver the gene editing tools directly to tumors. Their goal is to reduce how much standard treatment a patient needs in order to get the best result with fewer side effects. “Drug resistance is one of the biggest challenges in cancer care,” Rivera Torres said. “If we can overcome it with gene editing, we could give patients more time, better quality of life and a renewed sense of hope.” Kmiec added, “We are committed to moving this technology forward quickly while always keeping the patient in mind. The future of cancer treatment is personal, precise and, we believe, within reach.”

View all posts
Powered by